Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Morphogenesis Inc.
TAMPA, Fla., May 30, 2014 /PRNewswire/ -- Drs. Michael J.P. Lawman and Patricia D. Lawman, founders of the Tampa-based biotech firm Morphogenesis Inc., announce the publication of "Cancer Vaccines: Methods and Protocols," the most definitive work to date in the promising field of cancer vaccines.
As co-editors, the Lawmans worked for two-and-a-half years with leading cancer researchers, physicians, educators and subject matter experts from around the world to gather, catalogue and edit scientific and medical data for the 569-page book. It was published this year by Humana Press, a division of Springer Science+Business Media (www.springer.com).
Describing the book in its jacket copy, the publishers said it "aims to help guide researchers toward developing further generations of cancer vaccines that are both safe and efficacious, with the hope that cancer vaccines will be the standard of care in the very near future."
"Cancer immunotherapies, which include cancer vaccines, are ... cancer management/treatments that are finally becoming available to cancer patients around the world," the Lawmans write in the preface. "In contrast to chemo- and radio-therapies, cancer vaccines ... exert their effect by stimulating the body's immune systems to focus on and kill cancer cells alone."
"The purpose of the book was to bring as many methodologies as possible into one precise volume," said Dr. Michael Lawman. "There is a huge audience now in the cancer vaccine field, and we hope young and inspired researchers will apply the knowledge in the book to create the next generation of cancer vaccines."
Dr. Patricia Lawman called the 40-chapter book "a labor of love and an incredible amount of work." Because it examines in detail a massive collection of the world's knowledge about cancer immunotherapies, the Lawmans' work required making contact with dozens of leading authorities globally, acquiring, reviewing, questioning, researching, confirming and reconfirming immense amounts of highly technical information, and then generating uniformly-edited final copy and graphics for the editor in chief and publisher.
"I must congratulate you on such an excellent volume!" declared Methods in Molecular Biology Series Editor Dr. John Walker of the School of Life Sciences, University of Hertfordshire in the United Kingdom.
Morphogenesis (www.morphogenesis-inc.com) is a privately-held biotechnology company, founded by Drs. Michael and Patricia Lawman, which is structured to serve the rapidly growing cell therapy, biologics and tissue engineering markets. Morphogenesis has developed a multi-indication cancer therapy which educates the immune system to attack tumor cells throughout the body without damaging other cells or systems. Its subsidiary, Veterinary Oncology Services Inc., assists veterinary physicians in providing this non-toxic, personalized treatment for many types of cancers in cats, dogs and horses. For more information about the Lawmans and Morphogenesis, please visit www.morphogenesis-inc.com. For more information about Veterinary Oncology Services, please visit www.veterinaryoncologyservices.com.
©2012 PR Newswire. All Rights Reserved.